Is it safe?
Can TSHA take a bad year?
Taysha Gene Therapies, Inc. holds $228M more cash than debt, and is burning $28M a quarter, about 2.5 years of cover.
$228M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 8.22
Altman Z-score · safe zone, above 3
- Cash runway
- 2.5 years
Cash runway · burning $28M a quarter at the current rate
Details›
- Total debtQ1 2026
- $49M
- Cash and short-term investments
- $277M
- Net cash
- $228M
- EBITDA, trailing twelve months
- −$131M
- Operating profit, trailing twelve months
- −$133M
- Debt / equity
- 0.23×
- Annualised volatilitytwo years of daily moves
- 95%
- Worst drawdown on file
- −98%
- Below its 52-week high
- −14%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.